The first 60 days: Thymoma and thymic carcinoma
Thymoma and thymic carcinoma are rare tumours of the thymus gland in the chest. Thymomas grow slowly, often cause autoimmune diseases such as myasthenia gravis, and are usually cured by surgery; thymic carcinomas behave like other aggressive cancers and have few effective drugs. Below, week by week, is what OnCo's record of Thymoma and thymic carcinoma says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- SurgeonNamed in the standard of care for: Resectable (stage I-III), Locally advanced unresectable, Recurrent thymoma.
- Medical oncologistNamed in the standard of care for: Resectable (stage I-III), Locally advanced unresectable, Recurrent thymoma, Recurrent thymic carcinoma.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Resectable (stage I-III), Locally advanced unresectable.
- Transplant and cell therapy teamNamed in the standard of care for: Locally advanced unresectable.
- Palliative and supportive care teamNamed in the standard of care for: Locally advanced unresectable.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
- 1.Resectable (stage I-III)NCCN category Category 2A, NCCN Guidelines: Thymomas and Thymic Carcinomas
Complete thymectomy (minimally invasive for small tumours) after myasthenia control; post-operative radiotherapy for stage III, R1/R2, or thymic carcinoma.
- 2.Locally advanced unresectableNCCN category Category 2A, NCCN Guidelines: Thymomas and Thymic Carcinomas
Induction chemotherapy (CAP or carboplatin-paclitaxel) then surgery if resectable, otherwise definitive radiotherapy ± chemotherapy.
Re-resection of pleural or local recurrence; chemotherapy; octreotide + prednisone if octreoscan-positive; everolimus.
- 4.Recurrent thymic carcinomaNCCN category Category 2A, NCCN Guidelines: Thymomas and Thymic Carcinomas
Sunitinib or lenvatinib (REMORA); pembrolizumab (with strict cardiac monitoring, not in thymoma); everolimus; KIT inhibitors for KIT-mutant disease.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example WHO histotype and Masaoka-Koga / TNM stage, Completeness of resection, Acetylcholine-receptor antibodies, GTF2I L424H, KIT mutation), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Thymoma type A / AB, Thymoma type B1 / B2 / B3, Thymic carcinoma.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Resectable (stage I-III)
- For my situation (resectable (stage i-iii)), which of the standard options do you recommend and why?Guideline options include: Complete thymectomy (minimally invasive for small tumours) after myasthenia control; post-operative radiotherapy for stage III, R1/R2, or thymic carcinoma.
Locally advanced unresectable
- For my situation (locally advanced unresectable), which of the standard options do you recommend and why?Guideline options include: Induction chemotherapy (CAP or carboplatin-paclitaxel) then surgery if resectable, otherwise definitive radiotherapy ± chemotherapy.
- Am I a candidate for Cisplatin, Doxorubicin, Cyclophosphamide or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Recurrent thymoma
- For my situation (recurrent thymoma), which of the standard options do you recommend and why?Guideline options include: Re-resection of pleural or local recurrence; chemotherapy; octreotide + prednisone if octreoscan-positive; everolimus.
- Am I a candidate for Somatostatin analogues (octreotide, lanreotide), Everolimus, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Recurrent thymic carcinoma
- For my situation (recurrent thymic carcinoma), which of the standard options do you recommend and why?Guideline options include: Sunitinib or lenvatinib (REMORA); pembrolizumab (with strict cardiac monitoring, not in thymoma); everolimus; KIT inhibitors for KIT-mutant disease.
- Am I a candidate for Sunitinib, Lenvatinib, Pembrolizumab or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Lenvatinib, Sunitinib, Pembrolizumab, KC1036?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No randomised trials have ever been completed in thymic epithelial tumours”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Immunotherapy safety in a tumour that disturbs central tolerance”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- A Study of KC1036 in Patients with Advanced Thymic TumorsPhase 2 · recruiting · NCT05683886A Single-arm, Open, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of KC1036 in the Patients with Advanced Recurrent or Metastatic Thymic Tumors
- Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic CarcinomaPhase 2 · recruiting · NCT07324629A Phase II Clinical Study of Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma With Treatment Failure After Platinum-Based Therapy
- Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic CarcinomaPhase 1/2 · recruiting · NCT07598955A Phase 1/2, Open-Label, Target-Selected Study of Allogeneic CAR-NK Cells Directed to CD30, CD5, or Mesothelin in Patients With Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Thymoma and thymic carcinoma: the full pageThymoma and thymic carcinoma are rare tumours of the thymus gland in the chest. Thymomas grow slowly, often cause autoimmune diseases such as myasthenia gravis, and are usually cured by surgery; thymic carcinomas behave like other aggressive cancers and have few effective drugs.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Tumour mutational burden (TMB): How many mutations a tumour has.
- Immune-related adverse events (irAEs): Immune-related adverse events (irAEs) are the autoimmune side effects of checkpoint inhibitors: colitis, thyroid problems, rash, hepatitis, pneumonitis.
- Rare cancers: Rare cancers are those with fewer than about 6 new cases per 100,000 people per year.
Every term links to the glossary.